Completed PHASE3 INTERVENTIONAL 1-arm NCT00751738

Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)

A Multi-center, Open-label, Follow-up Study to Assess the Long-term Safety of 125 mg Per Day of Oral Azimilide Dihydrochloride in Patients With an Implantable Cardioverter Defibrillator

Sponsor: Forest Laboratories

Conditions Arrhythmias

Interventions azimilide dihydrochloride

Updated 7 times since 2017 Last updated: Jan 31, 2017 Started: Oct 31, 2002 Primary completion: Oct 31, 2005 Completion: Oct 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Arrhythmias, this trial is completed. The trial is conducted by Forest Laboratories and has accumulated 7 data snapshots since 2002. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Forest Laboratories

Data source: Forest Laboratories

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bad Bevensen, Germany , Baltimore, United States , Barcelona, Spain , Berlin, Germany , Boston, United States , Brandenburg, Germany , Bridgeport, United States , Brooklyn, United States , Bruges, Belgium , Burlington, United States and 72 more locations